<DOC>
	<DOCNO>NCT02314299</DOCNO>
	<brief_summary>This Phase 1/2 , open-label , dose-escalation clinical study , enrol 21 subject one two treatment group determine effect topical ocular administration low dose high dose MTP-131 give twice day subject Diabetic Macular Edema Age-Related Macular Degeneration .</brief_summary>
	<brief_title>A Study MTP-131 Topical Ophthalmic Solution Subjects With Diabetic Macular Edema Non-Exudative Intermediate Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>General : 1 . Adults age ≥18 ≤ 80 year 2 . Women childbearing potential must negative urine pregnancy test Baseline agree use highly effective method contraception throughout study 60 day last dose study drug . DME Treatment Group : 1 . Central subfield thickness ( CST ) ≥325 micron measure spectral domain optical coherence tomography ( SDOCT ) Screening Baseline Visits 2 . BCVA ( ETDRS ) good 20/25 study eye 3 . BCVA ( ETDRS ) worse 20/640 either eye AMD Treatment Group : 1 . Nonexudative , intermediate agerelated macular degeneration define eye ( ) extensive intermediate drusen ( 10 drusen 63μm 124μm ) large drusen ( 1 ≥125 μm ) evidence advance AMD ( i.e. , choroidal neovascularization macular atrophy ) 2 . BCVA ( ETDRS ) worse 20/400 either eye General : 1 . Inability selfadminister eye drop 2 . Current use likely need systemic medication know toxic lens , retina optic nerve ( example deferoxamine , chloroquine/hydroxychloroquine [ Plaquenil ] , tamoxifen , phenothiazine ethambutol ) 3 . Any medical condition , opinion investigator , would preclude safe participation study completion study requirement examination 4 . Have glycosylated hemoglobin ( HbA1c ) ≥ 12 % Ocular Conditions : 1 . Any ocular condition study eye opinion investigator would prevent improvement visual acuity successful completion study examination 2 . Ocular hypertension glaucoma , dry eye , ocular pathology study eye require treatment topical ophthalmic drop Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Macular edema</keyword>
	<keyword>Macular degeneration</keyword>
	<keyword>MTP-131</keyword>
	<keyword>Ocuvia™</keyword>
</DOC>